Objectives: This meta-analysis examined the relationship between two nonsynonymous polymorphisms (F31I and V57I) of the aurora kinase A (STK15) gene and breast cancer risk. Methods: A systematic search of the PubMed Õ and EMBASE TM databases was undertaken to identify case-control studies that investigated the relationship between STK15 gene polymorphisms and breast cancer risk. Results: This meta-analysis included seven case-control studies (5966 breast cancer cases; 7609 controls). Combined results, based on all seven studies, showed that breast cancer cases had a significantly higher frequency of the 31 Ile/Ile genotype. In a subgroup analysis by race, breast cancer cases had a significantly higher frequency of the 31 Ile/Ile genotype in Asians and Caucasians. Combined results, based on four studies, suggested that the STK15 V57I gene polymorphism was unlikely to be associated with breast cancer risk in either Asians or Caucasians. Conclusions: The present meta-analysis suggests that the STK15 F31I polymorphism is a strong predisposing risk factor for breast cancer, but no significant association existed between the STK15 V57I polymorphism and the risk of breast cancer.
Introduction
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer deaths among females, accounting for 23% of total cancer cases and 14% of cancer deaths, worldwide. 1 Breast cancer is now also the leading cause of cancer deaths among females in economically developing countries: a shift from the previous decade during which the most common cause of cancer deaths was cervical cancer. 1 The mechanism of breast carcinogenesis is still not fully understood, but breast cancers are generally considered to result from interactions between multiple environmental, dietary, hereditary, racial and socioeconomic risk factors. 2 Aurora kinase A, which is encoded by the STK15 gene (also known as BTAK), is involved in cell-cycle regulation, in particular the passage from G 2 to M, through the formation of mitotic spindles. 3 Due to this regulatory function, the STK15 gene has been hypothesized to be a potential cancer susceptibility gene. 3 The STK15 gene is located on chromosome 20q13.2. 4 Two nonsynonymous polymorphisms F31I (rs2273535) and V57I (rs1047972) have been identified in the STK15 gene. 5 Both polymorphisms are located within two conserved motifs in the N-terminal region of the STK15 gene. 5, 6 A thymine (T)/adenine (A) polymorphism located at nucleotide position 91 encodes a phenylalanine (Phe)-toisoleucine (Ile) (F31I) substitution at amino acid position 31. 5,6 A guanine (G)/A polymorphism at nucleotide 169 encodes a valine (Val)-to-Ile (V57I) substitution at amino acid position 57. 5, 6 STK15 gene polymorphisms have been reported to be associated with cancers of uterine, 7 lung, 8 oesophageal and ovarian tissue. 9, 10 Studies have been performed to clarify the association between these two polymorphisms (F31I and V57I) of the STK15 gene and breast cancer risk, [11] [12] [13] [14] [15] [16] [17] but have reported conflicting results. The purpose of this current meta-analysis was to undertake a detailed investigation of the relationship between STK15 gene polymorphisms F31I and V57I and breast cancer risk.
Materials and methods

Literature search strategy
A systematic search of articles listed in electronic databases (PubMed Õ and EMBASE TM ), published between January 1950 and December 2012, was conducted using the following key words: 'Aurora*' or 'STK15' or 'BTAK*', 'breast cancer' or 'breast carcinoma', 'polymorphism' or 'allele' or 'genetic variant'. No language restriction was used. Reference lists of the selected papers were screened by hand for potentially relevant new articles. If necessary, the corresponding authors of retrieved articles were contacted to acquire additional information. Furthermore, if more than one paper was published with an identical author using the same case series, the report with the larger sample size was selected. The list of articles was reviewed independently by two authors (K.Q. and C.W.).
Inclusion and exclusion criteria
The criteria employed to select studies for this systematic review were as follows: (i) independent epidemiological casecontrol studies (for humans only); (ii) a clear description of STK15 polymorphism in breast cancer cases and controls. The exclusion criteria were: (i) not an original paper (e.g. review or letter); (ii) duplicate publications; (iii) no control subjects.
Data extraction
Literature and eligible articles were searched by two authors (K.Q. and C.W.). The following data were extracted: the last name of the first author, publication year, country, study design, genotyping method, sample size and the results of the study. Methodological quality of the selected studies was independently assessed by two investigators (K.Q. and C.W.) using the nonrandomized study methodology quality assessment scale for nonrandomized trials.
Statistical analyses
Statistical analyses were performed using Stata Õ software (version 11.0; Stata Corp., College Station, TX, USA). The Mantel-Haenszel method was used for fixed effects and the method of DerSimonian and Laird was used for random effects to estimate the pooled odds ratio (OR) and corresponding 95% confidence interval (CI). A fixedeffects method was used if the result of the Q-statistic test was not significant; otherwise, the pooled estimates and confidence intervals were calculated based on a random-effects model. Publication bias was assessed by visual inspection of funnel plots, the Begg's rank correlation method and the Egger's weighted regression method. Subgroup analyses were performed on the basis of race. A P-value < 0.05 was considered statistically significant and all statistical tests were two sided.
Results
The initial database search identified 168 publications. After screening the titles and abstracts, 146 articles were excluded (86 did not study polymorphisms, 44 were not casecontrol studies, and 16 were not conducted in humans), which left 22 articles for a full publication review. Of these, a further 15 articles were excluded (13 were not casecontrol studies and two did not report useable data), leaving seven studies that met the inclusion criteria and were included in this current meta-analysis. [11] [12] [13] [14] [15] [16] [17] These seven studies included 5966 breast cancer cases and 7609 control subjects: [11] [12] [13] [14] [15] [16] [17] four were population-based case-control studies; 11, 12, 16, 17 three were hospital-based case-control studies. [13] [14] [15] Studies were conducted in the USA, UK and China (Table 1) .
Genotyping results for the seven studies that reported on the association between STK15 F31I gene polymorphisms and breast cancer are presented in Table 2 . [11] [12] [13] [14] [15] [16] [17] Combined results (based on all seven studies) showed that breast cancer cases had a significantly higher frequency of the Table 1 . Principal characteristics of seven studies included in a meta-analysis to investigate the relationship between aurora kinase A (STK15) gene polymorphisms F31I and V57I and breast cancer risk [11] [12] [13] [14] [15] [16] [17] . Table 3 ). Statistical heterogeneity was found by using the Q-statistic (P ¼ 0.003).
Publication bias was not found by the Begg's rank correlation method or Egger's weighted regression method. Four studies reported on the association between STK15 V57I gene polymorphism and breast cancer ( Table 2) . 12, 13, 16, 17 Combined results, based on all four studies, suggested that the STK15 V57I gene polymorphism was unlikely to be associated with breast cancer risk (Table 3 ). In the subgroup analysis by race, results demonstrated that the STK15 V57I gene polymorphism was unlikely to be associated with breast cancer risk in either Asian or Caucasian subjects. Statistical heterogeneity was not found by using the Q-statistic.
Discussion
This current meta-analysis of seven studies involving 5966 breast cancer cases and 7609 control subjects was conducted in order to make a more precise estimation of the association between two nonsynonymous polymorphisms (F31I and V57I) of the STK15 gene and breast cancer risk. Breast cancer cases had a significantly higher frequency of the 31 Ile/Ile genotype, not only in Asians but also in Caucasians. However, no significant association existed between the STK15 V57I polymorphism and the risk of breast cancer.
Studies investigating the association between genetic polymorphisms and breast cancer risk are being reported with rapidly increasing frequency. For example, a systematic review and pooled analysis of Table 2 . Genotype counts of the aurora kinase A (STK15) gene polymorphisms (F31I and V57I) reported by seven studies included in a meta-analysis to investigate the relationship between STK15 gene polymorphisms and breast cancer risk [11] [12] [13] [14] [15] [16] [17] . 10 studies, including 4644 cases and 5485 controls, suggested that rs1137101 and rs1137100 polymorphisms of the leptin receptor gene were significantly correlated with breast cancer risk; this study also found that the A allele of the rs1137101 variant and the G allele of the rs1137100 variant were low-penetrant risk factors for developing breast cancer. 18 A meta-analysis of nine studies, involving 2597 cases and 2618 controls, suggested that the matrix metalloproteinase-2-1306 cytosine (C)/T polymorphism may contribute to breast cancer susceptibility. 19 Another meta-analysis of 14 casecontrol studies (12 183 cases and 10 183 controls) suggested that the RAD51 variant 135C homozygote was associated with elevated breast cancer risk among carriers of the breast cancer type 2 susceptibility protein gene mutation. 20 A meta-analysis of 17 casecontrol studies (12 153 cases and 10 245 controls) suggested that the RAD51 G135C polymorphism was a low-penetrant risk factor for developing breast cancer. 21 The findings of a meta-analysis of 11 studies, including 5090 cases and 5214 controls, suggested that the xeroderma pigmentosum complementation group C PATþ/À polymorphism allele may be a low-penetrant risk factor for developing breast cancer. 22 Rare alleles at the v-Ha-ras Harvey rat sarcoma viral oncogene homologue-variable number tandem repeats locus were identified as possibly contributing to breast cancer susceptibility in a meta-analysis of 13 studies (1926 cases and 2800 controls). 23 A meta-analysis of seven studies (3177 cases and 4038 controls) suggested that the nicotinamide adenine dinucleotide phosphate hydrogen quinone oxidoreductase 1 proline187serine polymorphism may contribute to breast cancer development in Caucasians. 24 A thymidylate synthase (TYMS) gene enhancer region polymorphism may increase susceptibility to breast cancer in the Caucasian population, and a TYMS gene 3 0 -untranslated region polymorphism may be a genetic determinant for developing breast Table 3 . Meta-analysis of aurora kinase A (STK15) gene polymorphisms F31I and V57I, and breast cancer risk [11] [12] [13] [14] [15] [16] [17] . cancer in the Asian population, as demonstrated by a meta-analysis of 10 eligible studies. 25 A meta-analysis of 16 studies (involving 23 445 subjects) suggested that the sulphotransferase 1A1 codon 213 polymorphism may be associated with breast cancer susceptibility, based on data from hospital-based studies. 26 A meta-analysis of 13 case-control studies (10 236 cases and 13 143 controls) indicated that the tumour necrosis factor-a 308 A allele may be an important protective factor for breast cancer in European individuals. 27 Another meta-analysis of 30 case-control studies (15901 cases and 18 757 controls) suggested that the glutathione S-transferase pi gene Ile105Val polymorphism may increase susceptibility to breast cancer in the Asian population. 28 A meta-analysis of seven casecontrol studies, including 26 015 cases and 33 962 controls, suggested that the mitogenactivated protein kinase kinase kinase 1 rs889312 C allele was a low-penetrant risk factor for developing breast cancer. 29 The mechanism by which the STK15 F31I polymorphism affects breast cancer risk is unclear. The F31I polymorphism is located within a conserved motif in the N-terminal region of the STK15 gene. 5, 6 This motif could be related to ubiquitindependent degradation in early G 1 that is dependent on the C-terminal degradation box domain; it might also serve as a localization domain to target the protein to the centrosome in a microtubule-dependent manner. 30, 31 The Ile31 variant transforms rat1 cells more potently than the more common Phe31 variant. 6 The STK15 31 Ile/Ile genotype has been associated with a Figure 1 . Meta-analysis of the association between the aurora kinase A (STK15) F31I gene polymorphism and risk of breast cancer. [11] [12] [13] [14] [15] [16] [17] ID, identity; OR, odds ratio; CI, confidence interval. significantly increased risk of uterine and ovarian cancer. 7, 10 The present meta-analysis had several limitations that should be mentioned. First, relatively small sample sizes and significant heterogeneity were observed in the metaanalysis of STK15 F31I gene polymorphisms and breast cancer. Secondly, because many environmental factors may affect breast cancer susceptibility, all of our current findings might be due to interactions between the genetic background and multiple environmental factors. Thirdly, because of the lack of individual patient data, it was not possible to perform an adjustment estimate. Finally, this meta-analysis pooled genetic association studies published between 2004 and 2006; all of these studies were conducted before the 'Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement' was published. 32 Therefore, the studies included in this current meta-analysis did not fulfil all of the STROBE checklist items.
Despite these limitations, this current meta-analysis also had some advantages. First, a comprehensive search strategy based on computer-assisted and manual searching allowed all eligible studies to be included. Secondly, no publication bias was found, which would suggest a robust result.
In conclusion, the findings of this present meta-analysis suggest that the STK15 F31I polymorphism is a strong predisposing risk factor for breast cancer. Furthermore, no significant association existed between the STK15 V57I polymorphism and the risk of breast cancer.
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